Vacuum Polarization and Dynamical Chiral Symmetry Breaking: Phase Diagram of QED with Four-Fermion Contact Interaction

We study chiral symmetry breaking for fundamental charged fermions coupled electromagnetically to photons with the inclusion of four-fermion contact self-interaction term. We employ multiplicatively renormalizable models for the photon dressing function and the electron-photon vertex which minimally ensures mass anomalous dimension = 1. Vacuum polarization screens the interaction strength. Consequently, the pattern of dynamical mass generation for fermions is characterized by a critical number of massless fermion flavors above which chiral symmetry is restored. This effect is in diametrical opposition to the existence of criticality for the minimum interaction strength necessary to break chiral symmetry dynamically. The presence of virtual fermions dictates the nature of phase transition. Miransky scaling laws for the electromagnetic interaction strength and the four-fermion coupling, observed for quenched QED, are replaced by a mean-field power law behavior corresponding to a second order phase transition. These results are derived analytically by employing the bifurcation analysis, and are later confirmed numerically by solving the original non-linearized gap equation. A three dimensional critical surface is drawn to clearly depict the interplay of the relative strengths of interactions and number of flavors to separate the two phases. We also compute the beta-function and observe that it has ultraviolet fixed point. The power law part of the momentum dependence, describing the mass function, reproduces the quenched limit trivially. We also comment on the continuum limit and the triviality of QED.Comment: 9 pages, 10 figure

On Dark Matter Annihilation in the Local Group

Under the hypothesis of a Dark Matter composed by supersymmetric particles like neutralinos, we investigate the possibility that their annihilation in the haloes of nearby galaxies could produce detectable fluxes of $\gamma$-photons. Expected fluxes depend on several, poorly known quantities such as the density profiles of Dark Matter haloes, the existence and prominence of central density cusps and the presence of a population of sub-haloes. We find that, for all reasonable choices of Dark Matter halo models, the intensity of the $\gamma$-ray flux from some of the nearest extragalactic objects, like M31, is comparable or higher than the diffuse Galactic foreground. We show that next generation ground-based experiments could have the sensitivity to reveal such fluxes which could help us unveiling the nature of Dark Matter particles.Comment: 11 pages, 10 figures. Accepted for publication in Phys. Rev. D.; added a new paragraph on the detectability of Galactic sub-halos in our Galaxy; added a discussion on their model dependence. The relation of our results with the "CDM crisis" issue has also been adde

Two photon annihilation of Kaluza-Klein dark matter

We investigate the fermionic one-loop cross section for the two photon annihilation of Kaluza-Klein (KK) dark matter particles in a model of universal extra dimensions (UED). This process gives a nearly mono-energetic gamma-ray line with energy equal to the KK dark matter particle mass. We find that the cross section is large enough that if a continuum signature is detected, the energy distribution of gamma-rays should end at the particle mass with a peak that is visible for an energy resolution of the detector at the percent level. This would give an unmistakable signature of a dark matter origin of the gamma-rays, and a unique determination of the dark matter particle mass, which in the case studied should be around 800 GeV. Unlike the situation for supersymmetric models where the two-gamma peak may or may not be visible depending on parameters, this feature seems to be quite robust in UED models, and should be similar in other models where annihilation into fermions is not helicity suppressed. The observability of the signal still depends on largely unknown astrophysical parameters related to the structure of the dark matter halo. If the dark matter near the galactic center is adiabatically contracted by the central star cluster, or if the dark matter halo has substructure surviving tidal effects, prospects for detection look promising.Comment: 17 pages, 3 figures; slightly revised versio

Supersymmetric dark matter in M31: can one see neutralino annihilation with CELESTE?

It is widely believed that dark matter exists within galaxies and clusters of galaxies. Under the assumption that this dark matter is composed of the lightest, stable supersymmetric particle, assumed to be the neutralino, the feasibility of its indirect detection via observations of a diffuse gamma-ray signal due to neutralino annihilations within M31 is examined. To this end, first the dark matter halo of the close spiral galaxy M31 is modeled from observations, then the resultant gamma-ray flux is estimated within supersymmetric model configurations. We conclude that under favorable conditions such as the rapid accretion of neutralinos on the central black hole in M31 and/or the presence of many clumps inside its halo with $r^{-3/2}$ inner profiles, a neutralino annihilation gamma-ray signal is marginally detectable by the ongoing collaboration CELESTE.Comment: Latex, 32 pages, 12 figures, 5 table

A potential WIMP signature for the caustic ring halo model

Weakly Interacting Massive Particle (WIMP) direct detection event rate calculations usually rely on fairly simple, essentially static, analytic halo models. This is largely since the resolution of numerical simulations is not yet large enough to allow the full numerical calculation of the WIMP density and velocity distribution. In this paper we study the direct detection rate, in particular its energy dependence and annual modulation, for the caustic ring halo model. In this model, which uses simple assumptions to model the infall of dark matter onto the halo, the distribution of the cold dark matter particles at the Earth's location has a series of peaks in velocity space. We find that the sign of the annual modulation in the event rate changes as a function of recoil energy. These effects provide a potentially distinctive experimental signal.Comment: 6 pages, 3 figures. Version to appear in Phys. Rev. D. Comparsion with DAMA annual modulation data replaced with qualitative discussio

Signatures of Hierarchical Clustering in Dark Matter Detection Experiments

In the cold dark matter model of structure formation, galaxies are assembled hierarchically from mergers and the accretion of subclumps. This process is expected to leave residual substructure in the Galactic dark halo, including partially disrupted clumps and their associated tidal debris. We develop a model for such halo substructure and study its implications for dark matter (WIMP and axion) detection experiments. We combine the Press-Schechter model for the distribution of halo subclump masses with N-body simulations of the evolution and disruption of individual clumps as they orbit through the evolving Galaxy to derive the probability that the Earth is passing through a subclump or stream of a given density. Our results suggest that it is likely that the local complement of dark matter particles includes a 1-5% contribution from a single clump. The implications for dark matter detection experiments are significant, since the disrupted clump is composed of a `cold' flow of high-velocity particles. We describe the distinctive features due to halo clumps that would be seen in the energy and angular spectra of detection experiments. The annual modulation of these features would have a different signature and phase from that for a smooth halo and, in principle, would allow one to discern the direction of motion of the clump relative to the Galactic center.Comment: 26 pages, 18 figure

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years